Abstract
Over the past decade, the development and use of targeted immunotherapies in the treatment of solid organ and hematologic malignancies have revolutionized the field of oncology. Whereas prior cancer treatments had largely relied on killing tumor cells with nonspecific cytotoxic therapies and
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have